Serzone: Black Box to Jury Box?
December 1, 2002
photo-1In the months following the decision of the U.S. Food and Drug Administration and Bristol-Myers Squibb Co., to include a Black Box warning with Serzone (nefazodone) to advise patients that the drug has been associated with liver damage that may require a liver transplant, the products liability litigation involving the antidepressant's manufacturer has grown by leaps and bounds. photo-2 The plaintiffs, who have allegedly suffered liver damage or liver necrosis, are pursuing claims against Bristol-Myers Squibb that assert allegations under theories of strict liability including failure to warn and defective product design, negligence and breach of express and implied …
UPCOMING CONFERENCES
![](https://harrismartin.s3.amazonaws.com/media/CACHE/images/uploads/conferences/iStock-115753557_fLooJhx/ebadaa70c9ae4eba2f27c08bcd68c09c.jpg)
HarrisMartin's Midwest Asbestos Litigation Conference
September 27, 2024 - St. Louis, MO
Four Seasons Hotel, St. Louis